Action of the Disintegrin Contortrostatin on Breast Cancer Cell Primary Cultures

Ifigeneia Marinou, Sophia Havaki, Nikos Goutas, Dimitrios Vlachodimitropoulos, Georgios Baltatzis, Eumorphia G. Konstantakou, Dimitrios J. Stravopodis, Dimitrios G. Koudoumas, Evangelos Marinos, Mirsini Kouloukoussa

1st Department of Pathology, Medical School, University of Athens, Athens, Greece.
Department of Cell Biology and Biophysics, Faculty of Biology, University of Athens, Athens, Greece.
Laboratory of Experimental Surgery and Surgical Research, University of Athens, Athens, Greece.
Laboratory of Forensic Medicine and Toxicology, Medical School, University of Athens, Athens, Greece.
Laboratory of Histology and Embryology, Medical School, University of Athens, Athens, Greece.

DOI: 10.4236/abcr.2013.24026                

Abstract

Integrins mediate cell adhesion to the extracellular matrix (ECM). In particular, integrin alphavbeta3 recognizes the RGD motif as a ligand-binding site on various extracellular molecules of the extracellular matrix. Integrin aphavbeta3 has been associated with high malignant potential in breast cancer cells, and has signalized the onset of widespread metastasis. In recent years, several antagonists of integrin alphavbeta3, including snake venom disintegrins, have been used as potential anti-cancer agents. In the present work, the effect of contortrostatin, a disintegrin isolated from the venom of the snake Agkistrodon contortrix, was studied on primary cultures of human breast cancer cell. Scanning and transmission electron microscopy were employed in order to examine alterations in cell morphology and fluorescent microscopy and visualize changes in distribution of integrin alphavbeta3 and talin. Fluorescent localization of caspase 8 was made in order to visualize any sign of proapoptotosis and western immunoblotting of integrin, talin and annexin was undertaken in order to identify changes. The results suggest that the snake venom contortrostatin seriously affects cell morphology, adhesion and mobility and induces breast cancer cells to apoptosis.

Keywords

Breast Cancer; Disintegrins; Contortrostatin; Integrin Alphavbeta3; Apoptosis; Primary Cultures

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	R. E. Coleman, P. Smith and R. D. Rubens, “Clinical Course and Prognostic Factors Following Bone Recurrence from Breast Cancer,” British Journal of Cancer, Vol. 77, No. 2, 1998, pp. 336-340. http://dx.doi.org/10.1038/bjc.1998.52
[2]	R. O. Hynes, “Integrins: Versatility, Modulation, and Signaling in Cell Adhesion,” Cell, Vol. 69, No. 1, 1992, pp. 11-25. http://dx.doi.org/10.1016/0092-8674(92)90115-S
[3]	A. Cheresh, “Structural and Biologic Properties of Integrin Mediated Cell Adhesion,” Clinical Laboratory Medicine, Vol. 12, No. 2, 1992, pp. 217-236.
[4]	A. L. Berrier and K. M. Yamada, “Cell-Matrix Adhesion,” Journal of Cell Physiology, Vol. 213, No. 3, 2007, pp. 565-573. http://dx.doi.org/10.1002/jcp.21237
[5]	F. G. Giancotti and F. Mainiero, “Integrin-Mediated Adhesion and Signaling in Tumorgenesis,” Biochimica Biophysica Acta, Vol. 1198, No. 1, 1994, pp. 47-64. http://dx.doi.org/10.1016/0304-419X(94)90005-1
[6]	P. Jiang, A. Enomoto and M. Takahashi, “Cell Biology of the Movement of Breast Cancer Cells: Intracellular Signaling and the Actin Cytoskeleton,” Cancer Letters, Vol. 284, No. 2, 2009, pp. 122-130. http://dx.doi.org/10.1016/j.canlet.2009.02.034
[7]	C. Brakebusch, D. Bouvard, F. Stanchi, T. Sakai and R. Fassler, “Integrins in Invasive Growth,” Journal of Clinical Investigation, Vol. 109, No. 8, 2002, pp. 999-1006. http://dx.doi.org/10.1172/JCI0215468
[8]	R. E. Hewitt, D. G. Powe, K. Morrell, E. Balley, I. H. Leach, I. O. Ellis and D. R. Turner, “Laminin and Collagen IV Subunit Distribution in Normal and Neoplastic Tissues of Colorectum and Breast,” British Journal of Cancer, Vol. 75, No. 2, 1997, pp. 221-229. http://dx.doi.org/10.1038/bjc.1997.37
[9]	M. Rolli, E. Fransvea, J. Pilch, A. Saven and B. Felding-Habermann, “Activated Integrin Alphavbeta3 Cooperates with Metalloproteinase MMP-9 in Regulating Migration of Metastatic Breast Cancer Cells,” Proceedings National Academy of Sciences of the USA, Vol. 100, No. 16, 2003, pp. 9482-9487. http://dx.doi.org/10.1073/pnas.1633689100
[10]	E. F. Plow, T. A. Haas, L. Zhang, J. Loftus and J. W. Smith, “Ligand Binding to Integrins,” Journal of Biological Chemistry, Vol. 275, No. 29, 2000, pp. 21785-21788. http://dx.doi.org/10.1074/ jbc.R000003200
[11]	K. Jacob, A. K. Bosserhoff, F. Wach, R. Knuchel, E. C. Klein, R. Hein and R. Buettner, “Characterization of Selected Strongly and Weakly Invasive Sublines of a Primary Human Melanoma Cell Line and Isolation of Subtractive cDNA Clones,” International Journal of Cancer, Vol. 60, No. 5, 1995, pp. 668-675. http://dx.doi.org/10.1002/ijc.2910600517
[12]	E. Kawahara, K. Imai, S. Kumagai, E. Yamamoto and I. Nakanishi, “Inhibitory Effects of Adhesion Oligopeptides on the Invasion of Squamous Carcinoma Cells with Special Rreference to Implication of av Integrins,” Journal of Cancer Research and Clinical Oncology, Vol. 121, No. 3, 1995, pp. 133-140. http://dx.doi.org/10.1007/BF01198094
[13]	N. Reinmuth, W. Liu, S. A. Ahmad, F. Fun, O. Stoeltzing, A. A. Parikh, C. D. Bucana, G. E. Gallick, M. A. Nickols, W. F. Westlin and L. M. Ellis, “Alphavbeta3 Integrin Antagonist S247 Decreases Colon Cancer Metastasis and Angiogenesis and Improves Survival in Mice,” Cancer Research, Vol. 63, No. 9, 2003, pp. 2079-2087. http://cancerres.aacrjournals.org/content/63/9/2079
[14]	D. G. Batt, J. J. Petraitis, G. C. Houghton, D. P. Modi, G. A. Cain, M. H. Corjay, S. A. Mousa, P. J. Bouchard, M. S. Forsythe, P.P. Harlow, F. A. Barbera, S. M. Spitz, R. R. Wexler and P. K. Jadhav, “Disubstituted Indazoles as Potent Antagonists of the Integrin Alpha(v)beta(3),” Journal of Medical Chemistry, Vol. 43, No. 1, 2000, pp. 41-58. http://dx.doi.org/10.1021/jm990049j
[15]	C. Barja-Fidalgo, A. L. Coelho, R. Saldanha-Gama, E. Helal-Neto, A. Mariano-Oliveira and M. S. Freitas, “Disintegrins: Integrin Selective Ligands Which Activate Integrin-Coupled Signaling and Modulate Leukocyte Functions,” Brazilian Journal of Medical and Biological Research, Vol. 38, No. 10, 2005, pp. 1513-1520. http://dx.doi.org/10.1590/S0100-879X2005001000008
[16]	D. Zhang, T. Pier, D. G. McNeel, G. Wilding and A. Friedl, “Effects of a Monoclonal Anti-Alphavbeta3 Integrin Antibody on Blood Vessels—A Pharmacodynamic Study,” Investigations of New Drugs, Vol. 25, No. 1, 2007, pp. 49-55. http://dx.doi.org/10.1007/s10637-006-9013-8
[17]	N. Moiseeva, S. D. Swenson, F. S. Markland Jr. and R. Bau, “Purification, Crystallization and Preliminary X-Ray Analysis of the Disintegrin Contortrostatin from Agkistrodon contortrix contortrix Snake Venom,” Acta Crystallographica D: Biological Crystallography, Vol. 58, No. 17, 2002, pp. 2122-2124. http://dx.doi.org/10.1107/S0907444902011204
[18]	M. A. McLane, S. Vijay-Kumar, C Marcinkiewicz, J. J. Calvete and S. Niewiarowski, “Importance of the Structure of the RGD-containing Loop in the Disintegrins Echistatin and Eristostatin for Recognition of αIIbβ3 and αvβ3 Integrins,” FEBS Letters, Vol. 391, No. 1-2, 1996, pp. 139-143. http://dx.doi.org/10.1016/ 0014-5793(96)00716-8
[19]	M. Trikha, Y. A. De Clerck and F. S. Markland, “Contortrostatin, a Snake Venom Disintegrin, Inhibits β1 Integrin-Mediated Human Metastatic Melanoma Cell Adhesion and Blocks Experimental Metastasis,” Cancer Research, Vol. 54, No. 18, 1994, pp. 4993-4998.
[20]	Q. Zhou, M.T. Nakada, P.C. Brooks, S.D. Swenson, M. R. Ritter, S. Argounova and C. Arnold, “Contortrostatin, a Homodimeric Disintegrin, Binds to Integrin αvβ5,” Biochemica Biophysica Research Communication, Vol. 267, No. 1, 2000, pp. 350-355. http://dx.doi.org/10.1006/bbrc.1999.1965
[21]	F. S. Markland and Q. Zhou, “Snake Venom Disintegrin: An Effective Inhibitor of Breast Cancer Growth and Dissemination,” American Chemical Society Symposia Series, Vol. 745, 2000, pp. 262-282. http://dx.doi.org/10.1021/bk-2000-0745.ch018
[22]	Q. Zhou, M. T. Nakada, C. Arnold and F. S. Markland, “Contortrostatin, a Dimeric Disintegrin from Agkistrodon contortrix contortrix, Inhibits Angiogenesis,” Angiogenesis, Vol. 3, No. 3, 1999, pp. 259-269. http://dx.doi.org/10.1023/A:1009059210733
[23]	Q. Zhou, M. Ritter and F. S. Markland, “Contortrostatin, a Snake Venom Protein, Which Is an Inhibitor of Breast Cancer Progression,” Molecular Biology of the Cell, Vol. 7, No. S425a, 1996.
[24]	Q. Zhou, R. P. Sherwin, C. Parrish, et al., “Contortrostatin, a Dimeric Disintegrin from Agkistrodon contortrix contortrix, Inhibits Breast Cancer Progression,” Breast Cancer Research and Treatment, Vol. 61, No. 3, 2000, pp. 249-260. http://dx.doi.org/10.1023/A:1006457903545
[25]	A. Georgoulis, S. Havaki, Y. Drosos, N. Goutas, D. Vlachodimitropoulos, V. Aleporou-Marinou, C. Kittas, E. Marinos and M. Kouloukoussa, “RGD Binding to Integrin AlphavBeta3 Affects Cell Motility and Adhesion in Primary Human Breast Cancer Cultures,” Ultrastructural Pathology, Vol. 36, No. 6, 2012, pp. 387-399. http://dx.doi.org/10.3109/01913123.2012.681834
[26]	F. S. Markland, “Snake Venoms and the Hemostatic System” Toxicon, Vol. 36, No. 12, 1998, pp. 1749-1800. http://dx.doi.org/10.1016/S0041-0101(98)00126-3
[27]	S. Schmitmeier, F. S. Markland and T. C. Chen, “Anti-Invasive Effect of Contortrostatin, a Snake Venom Disintegrin, and TNF-Alpha on Malignant Glioma Cells,” Anticancer Research, Vol. 20, No. 6B, 2000, pp. 4227-4233.
[28]	R. S. Karthikeyan, M. Karthigayan, Sri Balasubashi, S. Vijayalakshni and T. Balasubramanian, “Antitumor Effect of Snake Venom (Hydrophis spiralis) on Ehrlich Ascites Carcinoma Bearing Mice,” International Journal of Cancer Research, Vol. 3, No. 4, 2007, pp. 167-173. http://dx.doi.org/10.3923/ijcr. 2007.167.173
[29]	L. Contois, A. Akalu and P. C. Brooks, “Integrins as ‘Functional Hubs’ in the Regulation of Pathological Angiogenesis,” Seminars in Cancer Biology, Vol. 19, No. 5, 2009, pp. 318-328. http://dx.doi.org/10.1016/j.semcancer. 2009.05.002
[30]	Mahabeleshwar, G. H. Feng, W. D. R. Phillips and T. V. Byzova, “Integrin Signaling Is Critical for Pathological Angiogenesis,” Journal of Experimental Medicine, Vol. 203, No. 11, 2006, pp. 2495-2507. http://dx.doi.org/10.1084/jem.20060807
[31]	J. D. Hood and D. A. Cheresh, “Role of Integrins in Cell Invasion and Migration,” National Review of Cancer, Vol. 2, No. 2, 2002, pp. 91-100. http://dx.doi.org/10.1038/nrc727
[32]	J. Folkman, “Angiogenesis: An Organizing Principle for Drug Discovery?” National Review of Drug Discovery, Vol. 6, No. 4, 2007, pp. 273-286. http://dx.doi.org/10.1038/nrd2115
[33]	J. A. Nemeth, M. T. Nakada, M. Trikha, Z. Lang, M. S. Gordon, G. C. Jayson, R. Corringham, U. Prabhakar, H. M. Davis and R. A. Beckman, “Alpha-v Integrins as Therapeutic Targets in Oncology,” Cancer Investigation, Vol. 25, No. 7, 2007, pp. 632-646. http://dx.doi.org/10.1080/ 07357900701522638
[34]	G. C. Tucker, “Integrins: Molecular Targets in Cancer Therapy,” Current Oncology Reports, Vol. 8, No. 2, 2006, pp. 96-103. http://dx.doi.org/10.1007/s11912-006-0043-3
[35]	R. Minea, C. Helchowski, B. Rubino, K. Brodmann, S. Swenson and F. Markland Jr., “Development of a Chimeric Recombinant Disintegrin as a Cost-Effective Anti-Cancer Agent with Promising Translational Potential,” Toxicon, Vol. 59, No. 4, 2012, pp. 472-486. http://dx.doi.org/10.1016/j.toxicon. 2011.02.020
[36]	L. M. Ellis and D. A. Reardon, “Cancer: The Nuances of Therapy,” Nature, Vol. 458, No. 7236, 2009, pp. 290-292. http://dx.doi.org/10.1038/458290a
[37]	E. Lin, Q. Wang, S. Swenson, H. Jadvar, S. Groshen, W. Ye, F. S. Markland and J. Pinski, “The Disintegrin Contortrostatin in Combination with Docetaxel Is a Potent Inhibitor of Prostate Cancer in Vitro and in Vivo,” Prostate, Vol. 70, No. 12, 2010, pp. 1359-1370. http://dx.doi.org/10.1002/ pros.21173
[38]	S. Havaki, M. Kouloukoussa, K. Amawi, Y. Drosos, L. D. Arvanitis, N. Goutas, D. Vlachodimitropoulos, S. D. Vassilaros, E. Z. Katsantoni, I. Voloudakis-Baltatzis, V. Aleporou-Marinou, C. Kittas and E. Marinos, “Altered Expression Pattern of Integrin AlphavBeta3 Correlates with Actin Cytoskeleton in Primary Cultures of Human Breast Cancer,” Cancer Cell International, Vol. 7, No. 2, 2007, pp. 16-28. http://dx.doi.org/10.1186%2F1475-2867-7-16
[39]	P. G. Sells, “Animal Experimentation in Snake Venom Research and in Vitro Alternatives,” Toxicon, Vol. 42, No. 2, 2003, pp. 115-133. http://dx.doi.org/10.1016/S0041-0101(03)00125-9